Targeted radiotherapy for chemotherapy resistant neuroblastoma with I-131 metaiodobenzylguanidine (MIBG)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update:
28 Jan 2021
Price :
$35
*
-
Adis is an information provider.
-
Final gross price and currency may vary according to local VAT and billing address.
-
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
-
A link to download a PDF version of the trial profile will be included in your email receipt.